Annual CFF
$3.47 M
+$3.97 M+783.63%
31 December 2023
Summary:
AcelRx Pharmaceuticals annual cash flow from financing activities is currently $3.47 million, with the most recent change of +$3.97 million (+783.63%) on 31 December 2023. During the last 3 years, it has fallen by -$38.05 million (-91.65%).ACRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$68.00 K
-$9.01 M-100.76%
31 December 2023
Summary:
AcelRx Pharmaceuticals quarterly cash flow from financing activities is currently -$68.00 thousand, with the most recent change of -$9.01 million (-100.76%) on 31 December 2023.ACRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$3.47 M
-$5.36 M-60.75%
31 December 2023
Summary:
AcelRx Pharmaceuticals TTM cash flow from financing activities is currently $3.47 million, with the most recent change of -$5.36 million (-60.75%) on 31 December 2023.ACRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACRX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -91.7% | -100.6% | -91.7% |
| 5 y5 years | -76.0% | -6900.0% | -76.0% |
ACRX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -95.4% | -100.1% | -96.0% |
AcelRx Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $3.47 M(-783.6%) | -$68.00 K(-100.8%) | $3.47 M(-60.7%) |
| Sept 2023 | - | $8.94 M(-368.2%) | $8.83 M(-605.7%) |
| June 2023 | - | -$3.33 M(+60.9%) | -$1.75 M(+252.0%) |
| Mar 2023 | - | -$2.07 M(-139.1%) | -$496.00 K(-2.2%) |
| Dec 2022 | -$507.00 K(-101.2%) | $5.30 M(-423.5%) | -$507.00 K(-108.4%) |
| Sept 2022 | - | -$1.64 M(-21.4%) | $6.03 M(+15.8%) |
| June 2022 | - | -$2.08 M(0.0%) | $5.21 M(-0.0%) |
| Mar 2022 | - | -$2.08 M(-117.6%) | $5.21 M(-87.5%) |
| Dec 2021 | $41.51 M(+144.8%) | $11.84 M(-580.9%) | $41.51 M(+10.6%) |
| Sept 2021 | - | -$2.46 M(+18.2%) | $37.53 M(-21.0%) |
| June 2021 | - | -$2.08 M(-106.1%) | $47.52 M(-5.5%) |
| Mar 2021 | - | $34.22 M(+335.8%) | $50.26 M(+196.4%) |
| Dec 2020 | $16.96 M(+17.3%) | $7.85 M(+4.4%) | $16.96 M(+86.2%) |
| Sept 2020 | - | $7.52 M(+1031.1%) | $9.10 M(+190.7%) |
| June 2020 | - | $665.00 K(-27.4%) | $3.13 M(-81.8%) |
| Mar 2020 | - | $916.00 K(>+9900.0%) | $17.16 M(+18.8%) |
| Dec 2019 | $14.45 M(-80.7%) | $1000.00(-99.9%) | $14.45 M(-78.0%) |
| Sept 2019 | - | $1.55 M(-89.5%) | $65.81 M(-21.8%) |
| June 2019 | - | $14.70 M(-919.1%) | $84.14 M(+12.3%) |
| Mar 2019 | - | -$1.79 M(-103.5%) | $74.95 M(-0.1%) |
| Dec 2018 | $75.03 M(+508.6%) | $51.36 M(+158.3%) | $75.03 M(+229.3%) |
| Sept 2018 | - | $19.88 M(+260.9%) | $22.78 M(+42.3%) |
| June 2018 | - | $5.51 M(-419.9%) | $16.01 M(+52.3%) |
| Mar 2018 | - | -$1.72 M(+95.0%) | $10.51 M(-14.7%) |
| Dec 2017 | $12.33 M(<-9900.0%) | -$883.00 K(-106.7%) | $12.33 M(-6.7%) |
| Sept 2017 | - | $13.11 M(>+9900.0%) | $13.21 M(<-9900.0%) |
| June 2017 | - | $11.00 K(-88.2%) | -$43.00 K(-20.4%) |
| Mar 2017 | - | $93.00 K(>+9900.0%) | -$54.00 K(+107.7%) |
| Dec 2016 | -$26.00 K | $0.00(-100.0%) | -$26.00 K(-101.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2016 | - | -$147.00 K(<-9900.0%) | $2.48 M(-96.0%) |
| June 2016 | - | $0.00(-100.0%) | $61.54 M(+3.6%) |
| Mar 2016 | - | $121.00 K(-95.2%) | $59.39 M(-0.4%) |
| Dec 2015 | $59.63 M(+402.4%) | $2.51 M(-95.7%) | $59.63 M(+5.3%) |
| Sept 2015 | - | $58.91 M(-2840.0%) | $56.61 M(-8931.7%) |
| June 2015 | - | -$2.15 M(-682.7%) | -$641.00 K(-105.5%) |
| Mar 2015 | - | $369.00 K(-171.4%) | $11.68 M(-1.6%) |
| Dec 2014 | $11.87 M(-75.2%) | -$517.00 K(-131.2%) | $11.87 M(-28.6%) |
| Sept 2014 | - | $1.66 M(-83.7%) | $16.63 M(-73.3%) |
| June 2014 | - | $10.17 M(+1715.9%) | $62.19 M(+23.8%) |
| Mar 2014 | - | $560.00 K(-86.8%) | $50.24 M(+4.9%) |
| Dec 2013 | $47.88 M(-3.8%) | $4.24 M(-91.0%) | $47.88 M(-44.3%) |
| Sept 2013 | - | $47.22 M(-2756.0%) | $85.97 M(+132.4%) |
| June 2013 | - | -$1.78 M(-1.7%) | $37.00 M(-22.7%) |
| Mar 2013 | - | -$1.81 M(-104.3%) | $47.87 M(-3.8%) |
| Dec 2012 | $49.77 M(+0.3%) | $42.33 M(-2524.5%) | $49.77 M(+185.5%) |
| Sept 2012 | - | -$1.75 M(-119.2%) | $17.43 M(-9.8%) |
| June 2012 | - | $9.09 M(>+9900.0%) | $19.32 M(+22.8%) |
| Mar 2012 | - | $89.00 K(-99.1%) | $15.73 M(-68.3%) |
| Dec 2011 | $49.60 M(+1374.1%) | $10.00 M(+6747.9%) | $49.60 M(+29.2%) |
| Sept 2011 | - | $146.00 K(-97.3%) | $38.39 M(-14.8%) |
| June 2011 | - | $5.50 M(-83.8%) | $45.06 M(+17.3%) |
| Mar 2011 | - | $33.96 M(-2883.9%) | $38.40 M(+1041.0%) |
| Dec 2010 | $3.37 M(-71.7%) | -$1.22 M(-117.9%) | $3.37 M(-26.6%) |
| Sept 2010 | - | $6.82 M(-686.5%) | $4.58 M(-305.6%) |
| June 2010 | - | -$1.16 M(+8.8%) | -$2.23 M(+108.8%) |
| Mar 2010 | - | -$1.07 M | -$1.07 M |
| Dec 2009 | $11.88 M(-62.8%) | - | - |
| Dec 2008 | $31.90 M | - | - |
FAQ
- What is AcelRx Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for AcelRx Pharmaceuticals?
What is AcelRx Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of ACRX is $3.47 M
What is the all time high annual CFF for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high annual cash flow from financing activities is $75.03 M
What is AcelRx Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of ACRX is -$68.00 K
What is the all time high quarterly CFF for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high quarterly cash flow from financing activities is $58.91 M
What is AcelRx Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of ACRX is $3.47 M
What is the all time high TTM CFF for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high TTM cash flow from financing activities is $85.97 M